tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Celldex price target lowered to $48 from $56 at Citi

Citi lowered the firm’s price target on Celldex (CLDX) to $48 from $56 and keeps a Buy rating on the shares. The company will not pursue barzolvolimab in eosinophilic esophagitis following the Phase 2 data, the analyst tells investors in a research note. Citi believes the shares were pricing in little to no value for this indication. Any selloff on the Phase 2 data will likely be temporary, the firm contends.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1